These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 37980924)
1. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG; Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924 [TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027 [TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R; Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394 [TBL] [Abstract][Full Text] [Related]
4. PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. O'Brien SH; Li D; Mitchell LG; Hess T; Zee P; Yee DL; Newburger JW; Sung L; Rodriguez V Thromb Haemost; 2019 May; 119(5):844-853. PubMed ID: 30861550 [TBL] [Abstract][Full Text] [Related]
5. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M; N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112 [TBL] [Abstract][Full Text] [Related]
6. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Bistervels IM; Buchmüller A; Wiegers HMG; Ní Áinle F; Tardy B; Donnelly J; Verhamme P; Jacobsen AF; Hansen AT; Rodger MA; DeSancho MT; Shmakov RG; van Es N; Prins MH; Chauleur C; Middeldorp S; ; Lancet; 2022 Nov; 400(10365):1777-1787. PubMed ID: 36354038 [TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P; Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660 [TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M; Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737 [TBL] [Abstract][Full Text] [Related]
9. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142 [TBL] [Abstract][Full Text] [Related]
10. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P; Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776 [TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
12. Oral apixaban for the treatment of acute venous thromboembolism. Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI; N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982 [TBL] [Abstract][Full Text] [Related]
14. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230 [TBL] [Abstract][Full Text] [Related]
16. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539 [TBL] [Abstract][Full Text] [Related]
17. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606 [TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD; Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756 [TBL] [Abstract][Full Text] [Related]
19. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D; Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317 [TBL] [Abstract][Full Text] [Related]
20. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database. Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]